Logo image of XTNT

XTANT MEDICAL HOLDINGS INC (XTNT) Stock Fundamental Analysis

NYSEARCA:XTNT - US98420P3082 - Common Stock

0.632 USD
+0 (+0.72%)
Last: 9/3/2025, 8:04:00 PM
Fundamental Rating

2

Overall XTNT gets a fundamental rating of 2 out of 10. We evaluated XTNT against 190 industry peers in the Health Care Equipment & Supplies industry. XTNT may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, XTNT is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year XTNT has reported negative net income.
In the past year XTNT has reported a negative cash flow from operations.
In the past 5 years XTNT reported 4 times negative net income.
In the past 5 years XTNT reported 4 times negative operating cash flow.
XTNT Yearly Net Income VS EBIT VS OCF VS FCFXTNT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20M -40M -60M -80M

1.2 Ratios

The Return On Assets of XTNT (-12.51%) is comparable to the rest of the industry.
XTNT has a Return On Equity (-27.33%) which is in line with its industry peers.
Industry RankSector Rank
ROA -12.51%
ROE -27.33%
ROIC N/A
ROA(3y)-10.3%
ROA(5y)-11.34%
ROE(3y)-20.61%
ROE(5y)-25.18%
ROIC(3y)N/A
ROIC(5y)N/A
XTNT Yearly ROA, ROE, ROICXTNT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100 -100 200

1.3 Margins

Looking at the Gross Margin, with a value of 58.18%, XTNT is in line with its industry, outperforming 56.32% of the companies in the same industry.
In the last couple of years the Gross Margin of XTNT has declined.
The Profit Margin and Operating Margin are not available for XTNT so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 58.18%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.35%
GM growth 5Y-2.41%
XTNT Yearly Profit, Operating, Gross MarginsXTNT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50

More info and screens

2

2. Health

2.1 Basic Checks

XTNT does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for XTNT has been increased compared to 1 year ago.
XTNT has more shares outstanding than it did 5 years ago.
XTNT has a worse debt/assets ratio than last year.
XTNT Yearly Shares OutstandingXTNT Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
XTNT Yearly Total Debt VS Total AssetsXTNT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M

2.2 Solvency

Based on the Altman-Z score of -1.33, we must say that XTNT is in the distress zone and has some risk of bankruptcy.
XTNT's Altman-Z score of -1.33 is in line compared to the rest of the industry. XTNT outperforms 42.63% of its industry peers.
A Debt/Equity ratio of 0.51 indicates that XTNT is somewhat dependend on debt financing.
The Debt to Equity ratio of XTNT (0.51) is worse than 61.05% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.51
Debt/FCF N/A
Altman-Z -1.33
ROIC/WACCN/A
WACC9.21%
XTNT Yearly LT Debt VS Equity VS FCFXTNT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

XTNT has a Current Ratio of 2.34. This indicates that XTNT is financially healthy and has no problem in meeting its short term obligations.
XTNT has a Current ratio of 2.34. This is comparable to the rest of the industry: XTNT outperforms 45.79% of its industry peers.
A Quick Ratio of 1.03 indicates that XTNT should not have too much problems paying its short term obligations.
XTNT has a Quick ratio of 1.03. This is in the lower half of the industry: XTNT underperforms 75.26% of its industry peers.
Industry RankSector Rank
Current Ratio 2.34
Quick Ratio 1.03
XTNT Yearly Current Assets VS Current LiabilitesXTNT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

More info and screens

4

3. Growth

3.1 Past

XTNT shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -100.00%.
XTNT shows a strong growth in Revenue. In the last year, the Revenue has grown by 28.44%.
The Revenue has been growing by 12.64% on average over the past years. This is quite good.
EPS 1Y (TTM)-100%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%166.67%
Revenue 1Y (TTM)28.44%
Revenue growth 3Y28.5%
Revenue growth 5Y12.64%
Sales Q2Q%18.26%

3.2 Future

XTNT is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 27.75% yearly.
XTNT is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 3.31% yearly.
EPS Next Y83%
EPS Next 2Y36.84%
EPS Next 3Y27.75%
EPS Next 5YN/A
Revenue Next Year10.6%
Revenue Next 2Y0.34%
Revenue Next 3Y3.31%
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
XTNT Yearly Revenue VS EstimatesXTNT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 20M 40M 60M 80M 100M
XTNT Yearly EPS VS EstimatesXTNT Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2019 2020 2023 2024 2025 2026 2027 0 -5 -10 -15 -20

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for XTNT. In the last year negative earnings were reported.
Also next year XTNT is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
XTNT Price Earnings VS Forward Price EarningsXTNT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 -40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
XTNT Per share dataXTNT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 0.4 0.6 0.8

4.3 Compensation for Growth

A more expensive valuation may be justified as XTNT's earnings are expected to grow with 27.75% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y36.84%
EPS Next 3Y27.75%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for XTNT!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

XTANT MEDICAL HOLDINGS INC

NYSEARCA:XTNT (9/3/2025, 8:04:00 PM)

0.632

+0 (+0.72%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)08-12 2025-08-12/bmo
Earnings (Next)11-10 2025-11-10/bmo
Inst Owners57.58%
Inst Owner Change-9.48%
Ins Owners14.69%
Ins Owner Change-0.26%
Market Cap82.36M
Analysts85
Price Target1.79 (183.23%)
Short Float %0.03%
Short Ratio0.48
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)34.64%
Min EPS beat(2)-30.72%
Max EPS beat(2)100%
EPS beat(4)1
Avg EPS beat(4)-8.66%
Min EPS beat(4)-56.86%
Max EPS beat(4)100%
EPS beat(8)3
Avg EPS beat(8)37.09%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)0.27%
Min Revenue beat(2)-2.85%
Max Revenue beat(2)3.39%
Revenue beat(4)2
Avg Revenue beat(4)-0.92%
Min Revenue beat(4)-6.52%
Max Revenue beat(4)3.39%
Revenue beat(8)6
Avg Revenue beat(8)4.72%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)42.86%
EPS NY rev (3m)42.86%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0.31%
Revenue NY rev (3m)1.25%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.67
P/FCF N/A
P/OCF N/A
P/B 1.88
P/tB 2.87
EV/EBITDA N/A
EPS(TTM)-0.04
EYN/A
EPS(NY)-0.02
Fwd EYN/A
FCF(TTM)-0.07
FCFYN/A
OCF(TTM)-0.04
OCFYN/A
SpS0.94
BVpS0.34
TBVpS0.22
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -12.51%
ROE -27.33%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 58.18%
FCFM N/A
ROA(3y)-10.3%
ROA(5y)-11.34%
ROE(3y)-20.61%
ROE(5y)-25.18%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.35%
GM growth 5Y-2.41%
F-Score2
Asset Turnover1.28
Health
Industry RankSector Rank
Debt/Equity 0.51
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 105.54%
Cap/Sales 3.7%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.34
Quick Ratio 1.03
Altman-Z -1.33
F-Score2
WACC9.21%
ROIC/WACCN/A
Cap/Depr(3y)93.26%
Cap/Depr(5y)102.58%
Cap/Sales(3y)2.72%
Cap/Sales(5y)2.97%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-100%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%166.67%
EPS Next Y83%
EPS Next 2Y36.84%
EPS Next 3Y27.75%
EPS Next 5YN/A
Revenue 1Y (TTM)28.44%
Revenue growth 3Y28.5%
Revenue growth 5Y12.64%
Sales Q2Q%18.26%
Revenue Next Year10.6%
Revenue Next 2Y0.34%
Revenue Next 3Y3.31%
Revenue Next 5YN/A
EBIT growth 1Y37.42%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year167.51%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-12.94%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y26.12%
OCF growth 3YN/A
OCF growth 5YN/A